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Abstract
Background: In adult patients who are critically ill and mechanically ventilated, daily interruption of sedation (DSI)
is an effective method of improving sedation management, resulting in a decrease of the duration of mechanical
ventilation, the length of stay in the intensive care unit (ICU) and the length of stay in the hospital. It is a safe and
effective approach and is common practice in adult ICUs. For critically ill children it is unknown if DSI is effective
and feasible. The aim of this multicenter randomized controlled trial is to evaluate the safety and efficacy of daily
sedation interruption in critically ill children.
Methods/Design: Children between 0 and 18 years of age who require mechanical ventilation, with an expected
duration of at least 48 h and need for sedative infusion, will be included. After enrollment patients will be randomly
assigned to DSI in combination with protocolized sedation (intervention group) or protocolized continuous
sedation (control group). A sedation protocol that contains an algorithm for increasing and weaning of sedatives
and analgesics will be used. The sedative infusion will be restarted if the patient becomes uncomfortable or
agitated according to the sedation protocol. The primary endpoint is the number of ventilator-free days at 28 days.
Trial registration: NTR2030
Keywords: Pediatrics, Critical illness, Sedation, Daily sedation interruption
Background
Critically ill children are often sedated in order to pre-
vent discomfort or anxiety and to facilitate care. The
sedative drug of choice for the majority of critically ill
children is midazolam, often given together with analge-
sics such as morphine or fentanyl [1]. Doses are indi-
vidually titrated, based on sedation assessments, to reach
the optimal level of sedation. Both inadequate and exces-
sive sedation may have deleterious effects. Oversedation
delays recovery, promotes tolerance and leads to distres-
sing symptoms on withdrawal of the drugs [2]. Underse-
dation may result in increased distress and increased
adverse events, such as unplanned extubation, accidental
displacement of catheters and fighting the ventilator.
Despite the use of sedation algorithms, excessive se-
dation is a common problem in critically ill children recei-
ving continuous sedation [3]. In adults, the administration
of sedatives by continuous infusion is an independent pre-
dictor of a longer duration of mechanical ventilation as well
as a longer stay in the intensive care unit (ICU) and in the
hospital overall [4].
In adults, daily sedation interruption (DSI) improves
clinical outcome. Every day, sedative drug infusions are
interrupted and patients are allowed to ‘wake up’ from
their medicine-induced sleep. During this period, patients
are assessed for neurological recovery and readiness for
extubation, or resedated if required [5]. In adult intensive
care patients, DSI resulted in a significant decrease in the
duration of mechanical ventilation, the length of stay in
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the ICU and the length of stay in the hospital [6]. DSI is
also a safe approach: self-extubation and removal of cathe-
ters did not occur more frequently in patients treated with
DSI. Follow-up studies showed that DSI reduces the inci-
dence of complications associated with mechanical venti-
lation and reduced symptoms of post-traumatic-stress
disorder (PTSD) [7,8]. In the last few years, some studies
have confirmed the safety and efficacy of DSI [9,10], while
other studies did not find a positive effect of DSI on cli-
nical outcome [11,12]. Nevertheless, DSI is now routine
practice in adult ICUs [5,13]. An even more drastic ap-
proach of no sedative drugs at all has also been shown
to improve clinical outcome in adult intensive care pa-
tients [14].
For critically ill children, it is unknown if DSI is effect-
ive, feasible and safe. Data from adult ICU studies can-
not be automatically extrapolated to children. Important
differences in the use of sedative drugs between children
and adults have been described. In adult ICU patients,
propofol and remifentanyl are the drugs of choice, be-
sides midazolam, morphine or fentanyl. In children, pro-
pofol is contraindicated for prolonged (>24 h) sedation
because of the risk for propofol infusion syndrome [1].
Another important difference is that the elimination
half-life of many drugs varies between adults and chil-
dren, due to age-related changes in drug metabolism
and renal excretion. Also, the assessment of the sedative
level differs between adults and children. For example,
to assess wakefulness adult patients are asked to perform
actions on request, such as squeeze a hand or stick out
their tongue. In most pediatric ICUs (PICUs), 80% of ad-
missions are children <3 years of age. Younger children
cannot perform such instructions on request and the as-
sessment of their sedation level should include other pa-
rameters, such as non-verbal communication. Specific
instruments, such as the COMFORT scale, have been
developed and validated for assessing sedation levels in
critically ill children [15]. Finally, since younger children
cannot clearly communicate, their behavior is different
and there might be a greater intolerance of discomfort.
We identified two studies evaluating the feasibility of
DSI in children. In a pilot study in 30 ventilated children
DSI was compared with standard care [16]. DSI ap-
peared feasible and safe (similar rate of unintended extu-
bations and line removals) and reduced the amount of
sedatives administered. However, this trial was not suffi-
ciently powered to detect differences in clinical outcomes.
The second study performed by our group showed that in
20 neonates on extracorporeal membrane oxygenation
(ECMO), midazolam and morphine could be discontinued
following cannulation for a median of 10 h without ad-
verse events [17].
Recently, a study was published comparing DSI with
continuous sedation in children on mechanical ventilation
[18]. This study showed that DSI also improves outcomes
in pediatric patients. The length of mechanical ventilation
and duration of intensive care stay were significantly re-
duced in the interrupted sedation group (10.3 vs 7.1 days,
P = 0.021 and 14.1 vs 10.7 days, P = 0.002, respectively).
There were no differences in adverse events between
groups. Given the large differences in patient population
and ICU practices between this Indian ICU and the West-
ern setting, these results need further validation [19]. In
this Dutch multicenter study, efficacy and safety of daily
interruption of sedation in critically ill children will be
investigated.
Methods/Design
In this multicenter randomized controlled trial, we will
compare DSI combined with protocolized sedation with
standard of care (protocolized sedation only). This study is
a collaborative study between PICUs in The Netherlands.
Study population
Patients will be recruited from five tertiary medical-
surgical PICUs (Erasmus MC - Sophia Children’s Hospital,
Radboud University Nijmegen Medical Centre, Academic
Medical Centre of Amsterdam, Leiden University Medical
Centre and University Medical Centre Groningen).
Children between 0 and 18 years of age admitted to
the pediatric intensive care unit, who require mechanical
ventilation, with an expected duration of at least 48 h,
and need for sedative drugs can be included.
Inclusion criteria: age between 0 to 18 years, at least
37 weeks of post conceptual age, anticipated duration of
mechanical ventilation of at least 48 h, need for sedative/
analgesic drugs.
Exclusion criteria: anticipated death within 48 h or with-
drawal of life support, patients in whom level of sedation
cannot be scored due to underlying neurologic condition,
neurological, respiratory or cardiac instability that may not
tolerate inadequate sedation (for example, traumatic brain
injury, pulmonary hypertension), therapeutic hypothermia
after cardiopulmonary resuscitation, difficult airway, fixed
duration of mechanical ventilation, admission for ECMO,
admission to our PICU after transfer from another PICU
where the patient is already ventilated/sedated for >2 days,
withdrawal of informed consent.
Randomization
Within 24 h after intubation, parental informed consent
will be obtained. The morning after enrolment, patients
will be randomly assigned in a 1:1 ratio to DSI combined
with protocolized sedation (intervention group) or pro-
tocolized sedation alone (control group).
Stratified randomization will be used in combination
with random permuted blocks. Randomization will be
stratified with regards to age in three groups: 0 up to
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30 days, 30 days up to 2 years, and 2 years up to 18 years.
A biostatistician will carry out computer randomization
in advance. During the study period, the pharmacist will
have access to group allocation for preparation of study
medication, and each assignment is designated on a
paper enclosed in a numbered, opaque sealed envelope.
After informed consent is obtained, the appropriate en-
velope is placed in a study binder at the patient’s
bedside.
Intervention
After enrollment, patients will be randomly assigned to
one of two strategies: protocolized continuous sedation
combined with daily interruption of infusion of seda-
tives beginning 24 h after start of infusion (intervention
group) or protocolized continuous sedation alone (con-
trol group).
Protocolized sedation/standard of care
All study centers use a standardized sedation protocol that
contains an algorithm for increasing and weaning of seda-
tives and analgesics. It standardizes sedation management
and allows nurses to adapt medication based on validated
sedation scores (COMFORT behavior scale (COMFORT-
b), Nurse Interpretation of Sedation Score (NISS)). The
COMFORT-b is an adapted version of a scale that was ori-
ginally developed by Ambuel and colleagues in 1992 for
the assessment of distress in pediatric patients, except for
premature neonates and children with neurological dis-
eases and limited motor function [20]. It consists of six be-
havioral items: alertness, agitation, crying or in case of
artificial ventilation breathing reaction, body movements,
muscle tone and muscle tone in the face. A trained inten-
sive care nurse observes a patient for a 2-minute period,
during which all items are assessed on a five-point nu-
merical scale (scored 1 to 5). The most distressed be-
havior during the 2-minute period is scored. The total
COMFORT-b score is the total of all item scores, with a
minimal score of 6 and a maximal score of 30. The cut-
off points for sedation scores were established [21]. In
all participating PICUs, nurses have been trained to use
this scale. Interobserver variability was satisfactory, with
Cohen’s κ >0.65 for all nurses.
Upon admission to the ICU patients are evaluated for
the need of sedatives and analgesics according to standard
medical treatment protocols. In this protocol, initially, mid-
azolam is titrated (up to 300 μg/kg/h) according to prede-
fined COMFORT-b scores. Adequate sedation is defined as
a COMFORT-b score ≥11 and ≤22. A COMFORT-b score
of <11 implies oversedation, a score >22 undersedation.
When sedation is considered insufficient, morphine (up to
30 μg/kg/h) is given in addition to midazolam. In cases of
continuing distress and where sedation is still in-
adequate, other drugs, such as ketamine, clonidine, fentanyl,
lorazepam, propofol, and alimemazine are added. When
pain is also suspected, as defined by a high numeric ra-
ting scale score (NRS ≥4), additional morphine is given.
All study centers use this protocol, with only local diffe-
rences in the choice of additional agents to midazolam
and morphine (Additional file 1: Appendix).
Intervention group
After the first 24 h of mechanical ventilation, the patient is
assessed for a safety screen every morning at 10.00 AM,
after routine care. This safety screen ensures that interrup-
tion of sedation is safe for the patient. If the patient passes
the screen, the sedative/analgesic infusions will be discon-
tinued immediately; this can be delayed for planned proce-
dures. Analgesics needed for active pain will be continued
(for example, pleural drain, <24 h after surgery). A patient
passes the screen unless: he/she receives a sedative infu-
sion for active seizures, receives escalating sedative doses
due to ongoing agitation, receives neuromuscular blockers,
has evidence of increased intracranial pressure or if there
is cardiorespiratory instability. Patients who fail the test
will be reassessed after 24 h (Figure 1).
During interruption, the patient may wake up, and
therefore, patients will be monitored frequently. Patient
comfort will be assessed routinely every 2 h using the
COMFORT-b/NISS and NRS scores and at any time the
patient appears distressed. The COMFORT-b score will
be used to assess the level of sedation/wakefulness.
The sedative infusion will be started again: (a) if the
patient becomes uncomfortable or agitated, according to
the sedation protocol; or (b) if deemed necessary by the
clinical team for instability in cardiorespiratory parame-
ters, defined as the need to increase the ventilatory sup-
port or cardiovascular treatment (inotropes/fluid bolus),
not associated with the underlying disorder.
After a loading dose of midazolam (0.1 mg/kg, intraven-
ously), the sedative infusions will be restarted at half the
previous dose and then titrated according to the sedation
protocol by the nurse to achieve adequate sedation.
Control group
In the control patients, following the safety screen, a
blinded infusion will be started at the same rate and
dose as the patient was receiving. The level of sedation
will be assessed in a manner similar to the interruption
group. When assessments indicate distress, the study in-
fusion will be ceased and replaced by the sedative infu-
sion at a similar rate as before the interruption.
Blinding
Complete blinding after randomization was considered
unsafe. It would mean blinded multiple infusion concen-
tration/rate changes over time, leaving patients prone to
drug dosing mistakes. However, during interruption, all
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patients will receive one or more blinded infusions (pla-
cebo in the intervention group and current sedation in
the control group) prepared by the study pharmacist to
minimize bias. In this way, the caregiving nurse will be
blinded for placebo or current sedation during the inter-
ruption period. This will minimize bias in assessing the
sedation level of the patient. At the end of the interrup-
tion period, the caregiving nurse will open the envelope
that is placed in the study binder at the patient’s bedside
to identify group allocation and sedation will be resumed
at 50% (intervention group) or 100% (control group) of
the previous intravenous infusion rate. This infusion
rate is visible for the caregiving nurse and is therefore
not blinded. This procedure will be repeated on every
study day.
Follow-up
Quality of life and symptoms of PTSD will be assessed
3 months after pediatric intensive care treatment using
validated questionnaires.
Patients will be approached by telephone by the inves-
tigators. Quality of life will be determined using the
Child Health Questionnaire (CHQ). The CHQ is a gen-
eric health profile measure covering physical and psy-
chosocial domains that refer to the perceived health
status for the collective 4 weeks prior to completing the
questionnaire. Its structure and methodological approach
are similar to those of the Short Form 36 (SF-36) scale,
the most used quality of life measure in adults. We will
ask parents to complete the CHQ for patients aged
2 months to 18 years. Patients aged 12 to 18 years will also
be asked to complete the CHQ by themselves.
Symptoms of posttraumatic stress will be measured with
the Dutch Children’s Responses to Trauma Inventory
(CRTI). This is a 26-item self-report questionnaire for
children aged 8 to 18 years. The questionnaire covers
three subscales (intrusion, avoidance, hyperarousal) ac-
cording to the diagnostic symptoms as per the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) for PTSD and one subscale for non-specific re-
actions. The total score of symptoms of PTSD can be used
as an overall index of a child’s stress reaction following a
stressful event.
Endpoints
The main study endpoint is the number of ventilator-free
days at 28 days, defined as the number of days a patient
breathes without mechanical assistance for at least 48 h
consecutively from day 1 to day 28 after randomization.
Secondary outcomes are: total and average dose of mid-
azolam and morphine administered (mg/kg); number of
COMFORT behavior scores <11 (oversedation) and >22
Enrollment and 
randomization
COMFORT-b (CF) and NRS every 2 hours
Contact the researcher
Blinded placebo infusion
(daily sedative interruption)
Safety screen 
every 24 hours
Intervention group
(DSI+PS)
Control group
(PS)
Follow weaning 
scheme
pass
fail
Oversedation
Safety screen 
every 24 hours
Blinded infusion
(current sedation/analgesia)
pass
fail
Comfortable Uncomfortable / 
undersedation
Cardiorespiratory  
instability
No intervention
Control group:
restart sedation at 
previous dose
Intervention group:
restart sedation at 
half the previous 
dose
Titrate sedatives to achieve patient 
comfort according to sedation protocol
Figure 1 Flowchart of study design.
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(undersedation); use of additional sedative or analgesic
drugs during ventilation; total number of safety screen as-
sessments and number and reason for failure to pass; total
number and reasons for protocol deviations; adverse
events (autoextubation and reintubation, accidental dis-
placement of catheters and feeding tubes, pain, changes in
blood pressure, heart rate, respiratory rate or alarms in
those parameters (bradycardia/apneas) that need medi-
cation or adjustments in ventilator settings, need for soft
wrist restrainers); incidence of withdrawal symptoms
(Sophia Observation withdrawal Symptoms (SOS) scale);
length of stay in the intensive care unit (days); length of
stay in the hospital (days); organ failure free days, defined
as the number of days from day 1 to day 28 in which the
patient is without clinically significant organ dysfunction
(the Paediatric Logistic Organ Dysfunction score (PELOD)
will be used to define pediatric organ dysfunction); 30-day
mortality; costs at 28 days; quality of life at 3 months,
assessed by the Child Health Questionnaire; and incidence
of PTSD at 3 months.
Statistical methods
Sample size calculation
Our institutional admission data from 2008 showed that
168 children were mechanically ventilated for at least 48 h
in our pediatric intensive care unit with mean ventilator-
free days of 16.5 days (SD 9.9). Using these data, we calcu-
lated that a sample size of 100 patients per group is suffi-
cient to detect a clinically significant difference of 25% in
ventilator-free days (that is, mean 12.4 days in the inter-
vention versus 16.5 days in the intervention group), with a
power of 80%, based on a 2-tailed Mann–Whitney test
with a significance level of 5%.
Final evaluation
Data will be analyzed with an intention-to-treat approach.
Demographic and clinical characteristics will be described
using standard statistical analysis methods. Descriptive data
will be presented as percentages, means ± SD for normally
distributed variables, and medians ± interquartile ranges for
non-normally distributed variables.
We will use χ2 tests or Fisher’s exact tests to compare
the distribution of categorical variables between the study
groups, and the Mann–Whitney test to compare continu-
ous variables, including the primary outcome ventilator-
free days.
The number of ventilator-free days will also be com-
pared with correction for baseline variables (age, sex,
PELOD score and type of disease), using multiple linear
regression analysis.
To compare the effects of the two treatment protocols
on length of stay in the intensive care unit and in the hos-
pital, time-to-event analysis will be used. Kaplan-Meier
analysis and the log-rank test will be used to assess the
effect of the treatment protocols. These tests will also be
used to assess the effect of the treatment on 30-day mor-
tality. Cox proportional hazards analysis will be used to as-
sess differences between the study groups after adjustment
for the baseline variables mentioned previously.
All statistical tests will be two-tailed and the signifi-
cance level will be set at 0.05.
Ethical considerations
The study protocol has been evaluated and approved by
the institutional review board of Erasmus Medical Centre,
Rotterdam and by the local ethics committees of all par-
ticipating centers: Radboud University Nijmegen Medical
Centre, Academic Medical Centre of Amsterdam, Leiden
University Medical Centre and University Medical Centre
Groningen.
Written parental consent will be obtained from partic-
ipants. The study will be conducted according to the
principles of the declaration of Helsinki (version 2004)
and in accordance with the Medical Research Involving
Human Subjects Act (WMO).
This trial is registered in the Dutch Trialregister, located
at http://www.trialregister.nl, under number NTR2030.
Data and Safety Monitoring Board (DSMB)
All adverse events reported spontaneously by the subject
or observed by the investigator or staff will be recorded.
A continuous evaluation on adverse effects will be per-
formed by an independent DSMB. Adverse events are
defined as any undesirable experience occurring to a
subject during the clinical trial. If it appears that a dis-
proportionate number of adverse events occur in the
intervention group, the DSMB can decide that the study
must be terminated.
Trial status
The trial is currently enrolling patients. We expect to
finish patient recruitment in 2014.
Additional file
Additional file 1: Appendix. Sedation protocol.
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